GANCICLOVIR SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ganciclovir Sodium, and when can generic versions of Ganciclovir Sodium launch?
Ganciclovir Sodium is a drug marketed by Am Regent, Custopharm Inc, Fresenius Kabi Usa, Hikma, Par Sterile Products, Pharmascience Inc, Slate Run Pharma, and Steriscience. and is included in eight NDAs.
The generic ingredient in GANCICLOVIR SODIUM is ganciclovir sodium. There are twenty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ganciclovir sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ganciclovir Sodium
A generic version of GANCICLOVIR SODIUM was approved as ganciclovir sodium by HIKMA on July 16th, 2003.
Summary for GANCICLOVIR SODIUM
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 54 |
Clinical Trials: | 6 |
Patent Applications: | 57 |
Formulation / Manufacturing: | see details |
DailyMed Link: | GANCICLOVIR SODIUM at DailyMed |
Recent Clinical Trials for GANCICLOVIR SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Taiwan University | Phase 2/Phase 3 |
Huang Pacific Foundation | Phase 2/Phase 3 |
University of California, San Francisco | Phase 2/Phase 3 |
Pharmacology for GANCICLOVIR SODIUM
Drug Class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral |
Mechanism of Action | DNA Polymerase Inhibitors |